Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were down 0.9% during mid-day trading on Wednesday . The company traded as low as $2.05 and last traded at $2.18, with a volume of 63,363 shares traded. The stock had previously closed at $2.20.

A number of analysts have recently issued reports on CNAT shares. FBR & Co reissued an “outperform” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Tuesday, March 15th. Brean Capital reissued a “buy” rating and issued a $13.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, March 10th. Finally, Roth Capital started coverage on shares of Conatus Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.66.

The company’s 50-day moving average is $2.14 and its 200 day moving average is $2.24. The company’s market cap is $45.94 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same period in the prior year, the firm posted ($0.38) EPS. Analysts forecast that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current year.

A hedge fund recently raised its stake in Conatus Pharmaceuticals stock. Jennison Associates increased its position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, Holdings Channel reports. The institutional investor owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned 3.32% of Conatus Pharmaceuticals worth $2,933,000 at the end of the most recent quarter.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.